[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:hemophilia-a:coagulation-factor-viii":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Hemophilia A","Coagulation Factor VIII",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05611801","A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B",[12],"Phase 3","RECRUITING","2026-08-26T02:19:15.498463Z","2026-05-05T02:35:31.704024Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04131036","Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A",[],"2026-08-26T02:17:23.750999Z","2026-05-13T02:55:06.243016Z",{"nct_id":23,"title":24,"phases":25,"status":26,"updated_at":27,"content_modified":28},"NCT05768386","A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)",[],"ENROLLING_BY_INVITATION","2026-08-26T02:17:50.500039Z","2026-06-16T05:54:08.086333Z"]